Bernstein Reiterated Anthem (ANTM) As “Buy”; Has TP Of $312.0; Array Biopharma (ARRY) Shorts Down By 8.3%

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Anthem Inc has $300 highest and $133 lowest target. $199.37’s average target is -22.78% below currents $258.19 stock price. Anthem Inc had 65 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was initiated by Piper Jaffray with “Neutral” on Wednesday, January 4. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, July 30. The company was initiated on Thursday, June 16 by Bernstein. On Thursday, October 26 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock of Anthem, Inc. (NYSE:ANTM) has “Buy” rating given on Monday, October 2 by RBC Capital Markets. As per Thursday, July 30, the company rating was maintained by Oppenheimer. Cantor Fitzgerald upgraded the stock to “Overweight” rating in Friday, April 28 report. The firm has “Mkt Perform” rating given on Thursday, October 29 by FBR Capital. Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) on Monday, November 6 with “Buy” rating. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, January 28.

Array Biopharma Incorporated (NASDAQ:ARRY) had a decrease of 8.3% in short interest. ARRY’s SI was 20.66M shares in January as released by FINRA. Its down 8.3% from 22.53 million shares previously. With 2.81M avg volume, 7 days are for Array Biopharma Incorporated (NASDAQ:ARRY)’s short sellers to cover ARRY’s short positions. The SI to Array Biopharma Incorporated’s float is 15.2%. The stock decreased 2.44% or $0.36 during the last trading session, reaching $14.39. About 3.48 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since January 29, 2017 and is uptrending. It has outperformed by 159.81% the S&P500.

Anthem, Inc., through its subsidiaries, operates as a health benefits firm in the United States. The company has market cap of $66.29 billion. It operates through three divisions: Commercial and Specialty Business, Government Business, and Other. It has a 23.31 P/E ratio. The firm offers a spectrum of network managed care health benefit plans to large and small employer, individual, Medicaid, and Medicare markets.

Analysts await Anthem, Inc. (NYSE:ANTM) to report earnings on February, 7. They expect $1.25 earnings per share, down 28.98% or $0.51 from last year’s $1.76 per share. ANTM’s profit will be $320.95 million for 51.64 P/E if the $1.25 EPS becomes a reality. After $2.65 actual earnings per share reported by Anthem, Inc. for the previous quarter, Wall Street now forecasts -52.83% negative EPS growth.

The stock increased 2.72% or $6.84 during the last trading session, reaching $258.19. About 1.21M shares traded. Anthem, Inc. (NYSE:ANTM) has risen 31.86% since January 29, 2017 and is uptrending. It has outperformed by 15.16% the S&P500.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.84 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Since September 29, 2017, it had 0 insider purchases, and 6 sales for $13.29 million activity. The insider Robbins Andrew R sold $3.03 million. 38,865 Array BioPharma Inc. (NASDAQ:ARRY) shares with value of $478,428 were sold by LEFKOFF KYLE. On Friday, September 29 VAN LUNSEN GIL J sold $493,510 worth of Array BioPharma Inc. (NASDAQ:ARRY) or 39,928 shares. Haddock Jason sold $102,975 worth of stock or 7,500 shares. On Saturday, December 16 Squarer Ron sold $8.90 million worth of Array BioPharma Inc. (NASDAQ:ARRY) or 819,671 shares.